Bionano Genomics(BNGO)
icon
搜索文档
Bionano Genomics(BNGO) - 2022 Q3 - Earnings Call Transcript
2022-11-04 09:40
Bionano Genomics, Inc. (NASDAQ:BNGO) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Amy Conrad - Investor Relations Erik Holmlin - Chief Executive Officer Christopher Stewart - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Operator Good day, and welcome to the Bionano Genomics Third Quarter 2022 Earnings Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Amy Conrad from ...
Bionano Genomics(BNGO) - 2022 Q3 - Quarterly Report
2022-11-03 00:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________________ FORM 10-Q _________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file numb ...
Bionano Genomics, Inc. (BNGO) Presents at H.C. Wainwright 24th Annual Global Investment Conference (Transcript)
2022-09-13 00:09
Bionano Genomics, Inc. (NASDAQ:BNGO) H.C. Wainwright 24th Annual Global Investment Conference September 12, 2022 7:00 AM ET Company Participants Erik Holmlin - President and Chief Executive Officer Conference Call Participants Trevor Levy - H.C. Wainwright Trevor Levy Good afternoon, everyone. And thank you for joining the H.C. Wainwright 24th Annual Global Investment Hybrid Conference. My name is Trevor Levy and I'm on the Corporate Access Team at HC Wainwright. While we are hybrid this year, we're confide ...
Bionano Genomics(BNGO) - 2022 Q2 - Earnings Call Transcript
2022-08-05 09:14
Bionano Genomics, Inc. (NASDAQ:BNGO) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants Amy Conrad - Investor Relations Erik Holmlin - Chief Executive Officer Christopher Stewart - Chief Financial Officer Conference Call Participants Michael Okunewitch - Maxim Group Operator Good day and welcome to the Bionano Genomics’ Second Quarter 2022 Earnings Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Amy Conrad from Inve ...
Bionano Genomics(BNGO) - 2022 Q2 - Quarterly Report
2022-08-04 00:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________________ FORM 10-Q _________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO | --- | --- | --- | --- | ...
Bionano Genomics(BNGO) - 2022 Q1 - Earnings Call Transcript
2022-05-06 08:16
Bionano Genomics, Inc. (NASDAQ:BNGO) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Amy Conrad - Investor Relations Erik Holmlin - Chief Executive Officer Chris Stewart - Chief Financial Officer Conference Call Participants Michael Okunewitch - Maxim Group Operator Good day, and welcome to the Bionano Genomics First Quarter 2022 Earnings Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Amy Conrad from Investor Rel ...
Bionano Genomics(BNGO) - 2022 Q1 - Quarterly Report
2022-05-05 00:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________________ FORM 10-Q _________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO | --- | --- | --- | |--- ...
Bionano Genomics, Inc. (BNGO) CEO Erik Holmlin at 2nd Annual Maxim Group Virtual Growth Conference (Transcript)
2022-03-31 07:25
Bionano Genomics, Inc. (NASDAQ:BNGO) 2nd Annual Maxim Group Virtual Growth Conference March 30, 2022 3:30 PM ET Company Participants Erik Holmlin - Chief Executive Officer Conference Call Participants Jason McCarthy - Maxim Group Michael Okunewitch — Maxim Group Jason McCarthy Welcome back everyone. Today we are bringing you Erik Holmlin, the CEO of Bionano Genomics. Bionano’s developing Optical Genome Mapping or OGM which is a genomic interrogation technique that provides long range structural information ...
Bionano Genomics(BNGO) - 2021 Q4 - Earnings Call Transcript
2022-03-02 08:25
Bionano Genomics, Inc. (NASDAQ:BNGO) Q4 2021 Earnings Conference Call March 1, 2022 4:30 PM ET Company Participants Amy Conrad – Investor Relations Erik Holmlin – Chief Executive Officer Chris Stewart – Chief Financial Officer Conference Call Participants Sung Ji Nam – BTIG Destiny Buch – Ladenburg Thalmann Kevin DeGeeter – Oppenheimer Michael Okunewitch – Maxim Group Operator Good day, and welcome to the Bionano Genomics Fourth Quarter and Full Year 2021 Earnings Conference Call. Today’s conference is bein ...
Bionano Genomics(BNGO) - 2021 Q4 - Annual Report
2022-03-01 00:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM Commission File Number 001-38613 Bionano Genomics, Inc. | --- | --- | |-------------------------------------------------------------------------- ...